Marinus Pharmaceuticals I... (MRNS)
0.55
0.00 (0.00%)
At close: Feb 10, 2025, 3:59 PM
No 1D chart data available
| Bid | n/a |
| Market Cap | 30.37M |
| Revenue (ttm) | 30.36M |
| Net Income (ttm) | -135.55M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | -0.95 |
| Analyst | n/a |
| Ask | 0.55 |
| Volume | 1,100,953 |
| Avg. Volume (20D) | 1,807,779 |
| Open | 0.55 |
| Previous Close | 0.55 |
| Day's Range | 0.55 - 0.55 |
| 52-Week Range | 0.22 - 10.50 |
| Beta | 1.26 |
About MRNS
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 165
Stock Exchange NASDAQ
Ticker Symbol MRNS
Website https://marinuspharma.com
Next Earnings Release
Marinus Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+41.65%
Marinus Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
4 months ago
-82.49%
Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.
2 months ago · businesswire.com
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...